SMS Pharmaceuticals Limited (NSE:SMSPHARMA)
356.60
+0.10 (0.03%)
Aug 21, 2026, 3:29 PM IST
SMS Pharmaceuticals Revenue
SMS Pharmaceuticals had revenue of 2.07B INR in the quarter ending June 30, 2026, with 5.57% growth. This brings the company's revenue in the last twelve months to 8.98B, up 10.25% year-over-year. In the fiscal year ending March 31, 2026, SMS Pharmaceuticals had annual revenue of 8.87B with 13.30% growth.
Revenue (ttm)
8.98B
Revenue Growth
+10.25%
P/S Ratio
3.72
Revenue / Employee
6.11M
Employees
1,470
Market Cap
33.40B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 8.87B | 1.04B | 13.30% |
| Mar 31, 2025 | 7.83B | 734.85M | 10.36% |
| Mar 31, 2024 | 7.09B | 1.87B | 35.86% |
| Mar 31, 2023 | 5.22B | 21.77M | 0.42% |
| Mar 31, 2022 | 5.20B | -433.03M | -7.69% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 599.11B |
| Cipla | 280.68B |
| Apollo Hospitals Enterprise | 264.30B |
| Divi's Laboratories | 112.30B |
| Dishman Carbogen Amcis | 28.95B |
| Indraprastha Medical Corporation | 15.24B |
| Solara Active Pharma Sciences | 14.31B |
| Medi Assist Healthcare Services | 9.51B |
SMS Pharmaceuticals News
- 2 months ago - SMS Pharmaceuticals uncovers fraudulent claim of 85,000 shares - Business Upturn
- 2 months ago - Pharma firm hit by Rs 3 cr shareholder fraud, case booked - The Times of India
- 9 months ago - SMS Pharmaceuticals successfully concludes USFDA inspection at Vizag API facility - Business Upturn
- 9 months ago - SMS Pharmaceuticals shares jump 4% as VKT Pharma secures US FDA approval for reformulated Ranitidine - Business Upturn
- 9 months ago - SMS Pharmaceuticals’ VKT Pharma receives US FDA approval for reformulated Ranitidine - Business Upturn
- 1 year ago - SMS Pharma shares surge over 7% after USFDA grants EIR for Hyderabad facility - Business Upturn
- 1 year ago - SMS Pharmaceuticals Q1 Results: Revenue jumps 19% YoY to Rs 196.05 crore, Net profit up14% YoY - Business Upturn
- 1 year ago - SMS Pharmaceuticals share jump 6% after its Hyderabad facility clears USFDA inspection with zero observations - Business Upturn